CAS 873697-71-3
:Omecamtiv mecarbil
Description:
Omecamtiv mecarbil is a novel small molecule classified as a cardiac myosin activator, primarily investigated for its potential in treating heart failure. It functions by selectively enhancing the contractility of cardiac muscle without increasing intracellular calcium levels, which helps to improve cardiac output while minimizing the risk of arrhythmias. The compound is characterized by its unique mechanism of action that targets the myosin motor protein, thereby increasing the efficiency of cardiac muscle contraction. Omecamtiv mecarbil has been the subject of various clinical trials, demonstrating its ability to improve heart function in patients with reduced ejection fraction. Its pharmacokinetic profile indicates moderate absorption and a half-life that allows for once-daily dosing. Additionally, it is important to note that while promising, the long-term effects and safety profile of omecamtiv mecarbil continue to be evaluated in ongoing research. Overall, this compound represents a significant advancement in the pharmacological management of heart failure, aiming to enhance the quality of life for affected patients.
Formula:C20H24FN5O3
InChI:InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
InChI key:InChIKey=RFUBTTPMWSKEIW-UHFFFAOYSA-N
SMILES:C(C1=C(F)C(NC(NC=2C=CC(C)=NC2)=O)=CC=C1)N3CCN(C(OC)=O)CC3
Synonyms:- Ck-1827452
- Methyl 4-[[2-fluoro-3-[N′-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate
- Omecamtiv mecarbil
- 1-Piperazinecarboxylic acid, 4-[[2-fluoro-3-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-, methyl ester
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Omecamtiv mecarbil (CK-1827452)
CAS:Formula:C20H24FN5O3Purity:98%Color and Shape:SolidMolecular weight:401.4347Omecamtiv mecarbil
CAS:<p>Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic</p>Formula:C20H24FN5O3Purity:98% - 99.23%Color and Shape:SolidMolecular weight:401.43CK 1827452
CAS:Controlled Product<p>Applications CK 1827452 is a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.<br>References Meijs, M. et al.: Eur. J. Heart. Fail., 14, 232 (2012); Malik, F. et al.: J. Mol. Cell. Card., 51, 454 (2011)<br></p>Formula:C20H24FN5O3Color and Shape:NeatMolecular weight:401.43CK 1827452-d8
CAS:Controlled Product<p>Applications CK 1827452-d8 is the labeled analogue of CK 1827452 (C544000), a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.<br>References Meijs, M. et al.: Eur. J. Heart. Fail., 14, 232 (2012); Malik, F. et al.: J. Mol. Cell. Card., 51, 454 (2011)<br></p>Formula:C20H16D8FN5O3Color and Shape:BeigeMolecular weight:409.48



